LLY

Eli Lilly reported Q2 2026 results that easily topped consensus estimates, driven by surging sales of Zepbound and Mounjaro. The company raised its full-year 2026 revenue guidance to $85-87B from the prior $82-85B range.

Eli Lilly announced positive results from two additional late-stage trials of retatrutide, its next-generation obesity/GLP-1 drug, bringing total positive Phase 3 trials to five. Lilly confirmed it will file for regulatory approval in 2027, positioning retatrutide as the next pillar of its obesity franchise.

Eli Lilly reported positive late-stage clinical trial results for multiple next-generation obesity/diabetes drugs, including orforglipron (oral GLP-1 with no food/water restrictions) and retatrutide (triple-action), showing significant weight loss and additional benefits including sleep apnea reduction. Shares rose premarket on the data.

Eli Lilly presented clinical data on retatrutide (triple GIP/GLP-1/glucagon agonist) at the American Diabetes Association meeting, showing substantial reductions in blood sugar, body weight, knee osteoarthritis pain, and obstructive sleep apnea. Lilly's investor relations site confirmed the data release officially.

AI rally is pausing as 10Y yields hit 4.55% (+4.3% weekly), compressing growth multiples. VIX is up 11.5% in a week, signaling risk-off rotation. Healthcare (XLV +2.2% this week) is already outperforming, but the re-rating is early. Long large-cap healthcare with AI-driven pipeline exposure as the rotation accelerates.